Yourgene Health PLC ISO 15189:2012 accreditation received
01 Septiembre 2021 - 01:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
01 September 2021
`Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Yourgene Genomic Services receive ISO 15189:2012
accreditation
Validating its COVID-19 testing and sequencing services,
providing assurance of compliance to international standards to
deliver quality levels of performance and competence
Manchester, UK - 1 September 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that following
assessments by the UK accreditation service (UKAS), it has received
ISO 15189:2012 accreditation for its COVID-19 testing and
sequencing services, providing assurance that the Company's
Citylabs 1.0 laboratory in Manchester, meets internationally recognised gold standards.
Assessments under UKAS ensure that laboratories meet the
relevant requirements including the operation of a quality
management system and the ability to demonstrate that specific
activities are performed within the criteria set out in the
relevant standard . This achievement sets a solid foundation for
Yourgene, enabling the Company to have certificates and reports
accepted in over 80 countries around the world. ISO 15189:2012
accreditation provides confidence that Yourgene's medical
laboratories deliver quality levels of performance and competence
and confirms that the Company is operating a clinical service that
is safe, reliable and consistent conveying trust to stakeholders
and decision-makers and allows for a more rigorous system in
operation.
Lyn Rees, CEO of Yourgene commented: "We are so pleased to have
been accredited with this ISO standard as it serves to recognise
the quality levels of performance at our Citylab 1.0 laboratory.
Being a globally recognised accreditation opens up over 80
countries to Yourgene aiding our global operation."
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and infectious diseases.
The Group's flagship products include non-invasive prenatal tests
(NIPT) for Down's Syndrome and other genetic disorders, Cystic
Fibrosis screening tests, invasive rapid aneuploidy tests, and a
recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABRGDIGUXDGBB
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Premaitha (LSE:NIPT)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Premaitha (LSE:NIPT)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024